FDA Approves XATMEP — Azurity Pharmaceuticals, Inc.

# FDA Approves Azurity Pharmaceuticals' XATMEP Oral Methotrexate Formulation Azurity Pharmaceuticals has received FDA approval for XATMEP (methotrexate), an oral formulation of the widely-used cancer and autoimmune disease treatment, potentially capturing market share in the competitive methotrexate segment. The approval expands Azurity's oncology and specialty pharmaceutical portfolio, positioning the company to compete in a market currently dominated by established generic and branded methotrexate products.